NASDAQ NMS - GLOBAL MARKET · VYGR
+3.04% · +$0.0900 · Vol 292.7K
Market closed · last close 4:00 PM ET · price as of 16:59:38 ET
Voyager Therapeutics Inc

Voyager Therapeutics Inc

Biotechnology
$3.18
Card
Relationship Map

Follow $VYGR

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $VYGR by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
VYGR
Voyager Therapeutics Inc
Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: LOW · 5 of 6 factors measured · Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is VYGR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading VYGR catalysts
About Voyager Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2015
Employees
141
Country
US

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.13
Day high
$3.15
Day low
$3.05
Previous close
$3.09
52W high
$5.33
-40.26% from high
52W low
$3.00
8% of range
Market cap
$190.4M
EPS
$-1.9100
Beta
1.28
Shares out
61.6M
Volume
292.7K
0.67× rel vol
Avg volume
439.3K
VWAP
$3.09
Price history computed in-house
1W
+3.04%
1M
-6.08%
3M
-13.48%
1Y
-24.55%
YTD
-18.98%
SMA 50 $3.22 · below
SMA 200 $3.73 · below
52W position 8%

VYGR overview

Loading financial statements
Loading VYGR Form 4 filings
Public disclosures

Congress activity in VYGR

No receipt-qualified Congressional disclosure is present for VYGR in the cached public ledger.

Federal contracts

VYGR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for VYGR in this window.
Lobbying spend

VYGR lobbying filings, year to date.

Registered lobbying filings matched to Voyager Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for VYGR in this window.
Loading news for VYGR
Analyst ratings
Sovereign unlock shows live analyst consensus for VYGR.
Options
Sovereign unlock shows live options positioning for VYGR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.